# Ripretinib (QINLOCK®) According to Current SmPC

> **NCT06619275** · — · COMPLETED · sponsor: **iOMEDICO AG** · enrollment: 10 (actual)

## Conditions studied

- GIST - Gastrointestinal Stromal Tumor

## Interventions

- **DRUG:** Ripretinib

## Key facts

- **NCT ID:** NCT06619275
- **Lead sponsor:** iOMEDICO AG
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-17
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-09-15
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06619275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06619275, "Ripretinib (QINLOCK®) According to Current SmPC". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT06619275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*